The global molybdenum 99 market size was valued at USD 4.14 billion in 2025 and is projected to grow from USD 4.37 billion in 2026 to USD 6.70 billion by 2034, registering a CAGR of 5.5% during the forecast period from 2026 to 2034. North America dominated the molybdenum 99 market with a market share of 39.5% in 2025.
Molybdenum-99 is a radioactive isotope primarily used to produce technetium-99m, the most widely utilized radioisotope in diagnostic nuclear medicine imaging. It plays a critical role in detecting and monitoring conditions such as cancer, cardiovascular diseases, and neurological disorders. Demand is driven by the increasing number of diagnostic imaging procedures, expanding nuclear medicine applications, and investments in reliable isotope production and healthcare infrastructure.
Download a Free Sample To learn more about this report,
Molybdenum 99 Market trends are being driven by increasing investments in domestic production of medical isotopes to ensure a stable supply for nuclear medicine. Healthcare systems are focusing on reducing dependence on aging nuclear reactors and imported isotopes by supporting alternative production technologies and expanding local manufacturing capacity. The growing number of diagnostic imaging procedures using technetium-99m, which is derived from molybdenum-99, is further encouraging governments and private companies to strengthen isotope production infrastructure. These initiatives are supporting molybdenum 99 market growth by improving supply reliability for hospitals and diagnostic centers.
Molybdenum 99 Market trends are also being influenced by the growing transition toward low-enriched uranium (LEU) and non-HEU production technologies for medical isotopes. Manufacturers and research organizations are investing in innovative production methods that improve efficiency, reduce radioactive waste, and enhance supply chain resilience. At the same time, the increasing use of SPECT imaging for oncology, cardiology, and neurology is driving continuous demand for high-quality molybdenum-99. These technological advancements are strengthening molybdenum 99 market share by supporting sustainable isotope production and expanding access to nuclear diagnostic procedures.
Rising Demand for Nuclear Medicine Diagnostics
The molybdenum-99 market is experiencing steady growth due to the increasing use of nuclear medicine for the diagnosis of cardiovascular diseases, cancer, neurological disorders, and other chronic conditions. Molybdenum-99 is the parent isotope of technetium-99m, which is widely used in diagnostic imaging procedures because of its effectiveness and short half-life. Growing investments in healthcare infrastructure, expanding access to nuclear imaging services, and the increasing prevalence of chronic diseases are strengthening molybdenum-99 market demand across developed and emerging economies.
Limited Production Facilities and Short Isotope Shelf Life
The molybdenum-99 market faces restraints due to its dependence on a limited number of production reactors and processing facilities worldwide. Since molybdenum-99 has a short radioactive half-life, it must be produced, processed, and transported within a strict timeframe, making supply chain management highly complex. Planned reactor maintenance, unexpected shutdowns, and transportation delays can disrupt the global supply of medical isotopes, affecting hospitals and diagnostic centers.
Development of Non-Reactor Production Technologies
The molybdenum-99 market presents significant opportunities through the development of alternative production methods, including accelerator-based technologies and low-enriched uranium production processes. These innovations aim to improve supply security, reduce dependence on aging nuclear reactors, and support a more sustainable isotope production network. Increasing investments in domestic isotope manufacturing and modern production facilities are also expected to strengthen molybdenum-99 market share while improving long-term availability for medical imaging applications.
Maintaining Stable Global Supply and Regulatory Compliance
The molybdenum-99 market continues to face challenges in maintaining a consistent global supply while meeting strict nuclear safety and regulatory requirements. Producers must comply with rigorous quality standards, radiation safety protocols, and transportation regulations throughout the production and distribution process. At the same time, replacing aging production infrastructure and ensuring uninterrupted isotope availability require significant capital investment and international collaboration. Addressing these challenges will be essential to support the growing demand for nuclear medicine worldwide.
Request Customizationto receive a tailored report.
Non-highly Enriched Uranium Segment Dominated the Market with 68.7% Share in 2025
The non-highly enriched uranium segment dominated the global molybdenum-99 market with a 68.7% share in 2025, driven by the growing adoption of low-enriched uranium targets for Molybdenum-99 production. Increasing regulatory support for non-proliferation initiatives, improved production technologies, and the ability to ensure a stable isotope supply continue to strengthen the segment's leading position.
The highly enriched uranium segment is witnessing steady demand in selected production facilities where existing infrastructure continues to support its use. However, ongoing investments in alternative production methods and the gradual transition toward low-enriched uranium are influencing the long-term evolution of this segment.
Growing focus on supply chain security, modernization of isotope production facilities, and advancements in reactor and accelerator-based technologies are expected to further support the expansion of non-highly enriched uranium production over the coming years.
Medical Segment Dominated the Market with 75.4% Share in 2025
The medical segment dominated the global molybdenum-99 market with a 75.4% share in 2025, supported by the widespread use of technetium-99m derived from Molybdenum-99 in nuclear medicine diagnostics. Increasing demand for diagnostic imaging procedures, early disease detection, and expanding healthcare infrastructure continue to reinforce the segment's leading position.
The scientific research segment is witnessing steady growth as universities, research laboratories, and nuclear science organizations continue to utilize radioisotopes for experimental studies, isotope production research, and the development of advanced imaging technologies.
Increasing investments in nuclear medicine research, radiopharmaceutical innovation, and isotope production capabilities are expected to create additional opportunities across both medical and scientific research applications.
SPECT Segment Dominated the Market with 56.2% Share in 2025
The SPECT segment dominated the global molybdenum-99 market with a 56.2% share in 2025, driven by its extensive use in diagnosing cardiovascular diseases, cancer, neurological disorders, and other chronic conditions. The high clinical value of SPECT imaging and the broad availability of technetium-99m radiopharmaceuticals continue to support strong market demand.
The gamma camera segment is witnessing steady growth as healthcare providers continue to upgrade diagnostic imaging systems to improve image quality, workflow efficiency, and patient outcomes. Increasing adoption of advanced nuclear imaging technologies is supporting the expansion of this segment.
Continuous improvements in imaging equipment, hybrid diagnostic systems, and radiopharmaceutical development are expected to further enhance the use of both SPECT and gamma camera technologies across healthcare facilities worldwide.
Hospitals and Diagnostic Centers Segment Dominated the Market with 73.1% Share in 2025
The hospitals and diagnostic centers segment dominated the global molybdenum-99 market with a 73.1% share in 2025, driven by the high volume of nuclear medicine procedures performed for disease diagnosis and patient monitoring. Growing demand for non-invasive imaging, expanding diagnostic capabilities, and increasing availability of nuclear medicine services continue to strengthen the segment's leading position.
The research institutes segment is witnessing steady growth as academic institutions and nuclear research organizations expand their work in isotope production, radiopharmaceutical development, and advanced medical imaging technologies. Increasing public and private investments in healthcare research continue to support the segment's expansion.
Ongoing collaboration between healthcare providers, research institutions, and isotope manufacturers is expected to accelerate innovation and improve the availability of Molybdenum-99, supporting long-term growth across both end-user segments.
Speak to an Analystto discuss market opportunities.
North America molybdenum-99 market accounted for 39.5% of the global market, reaching USD 1.64 billion in 2025, and is projected to grow at a CAGR of 7.62% during the forecast period. Rising demand for nuclear medicine procedures, increasing adoption of diagnostic imaging, and growing investments in radioisotope production continue to drive regional market growth. Ongoing modernization of nuclear medicine infrastructure is also supporting market expansion.
The U.S. market was valued at USD 1.39 billion in 2025, making it the largest contributor in North America. Growing demand for diagnostic imaging procedures, expanding nuclear medicine applications, and increasing investments in domestic radioisotope production continue to strengthen market growth.
Canada's market reached USD 0.25 billion in 2025. The country's strong expertise in radioisotope production, expanding healthcare infrastructure, and increasing demand for nuclear diagnostic procedures continue to support steady market expansion.
Europe molybdenum-99 market accounted for 27.8% of the global market, reaching USD 1.15 billion in 2025, and is expected to register a CAGR of 7.34% during the forecast period. Rising demand for advanced diagnostic imaging, expanding nuclear medicine facilities, and increasing investments in healthcare infrastructure are driving regional growth. Ongoing research in medical isotopes is further supporting market development.
Germany's market accounted for USD 0.33 billion in 2025. Strong healthcare infrastructure, growing use of nuclear imaging, and increasing investment in advanced diagnostic technologies continue to support market growth.
The UK market was valued at USD 0.24 billion in 2025. Rising demand for nuclear medicine procedures, expanding diagnostic services, and continuous healthcare investments continue to contribute to market expansion.
Asia Pacific molybdenum-99 market accounted for 22.4% of the global market, valued at USD 0.93 billion in 2025, and is projected to register a CAGR of 9.18% during the forecast period. Expanding healthcare infrastructure, increasing cancer diagnosis rates, growing adoption of nuclear medicine, and rising investments in medical imaging continue to accelerate regional market growth.
Japan's market generated USD 0.17 billion in 2025. Increasing use of advanced diagnostic imaging, expanding nuclear medicine applications, and strong healthcare spending continue to support market growth.
China's market accounted for USD 0.48 billion in 2025, representing the largest share within Asia Pacific. Expanding nuclear medicine facilities, increasing healthcare investments, and rising demand for radioisotopes used in diagnostic imaging continue to drive market expansion.
Latin America molybdenum-99 market accounted for 5.9% of the global market, reaching USD 0.24 billion in 2025, and is projected to grow at a CAGR of 7.21% during the forecast period. Improving healthcare infrastructure, increasing access to diagnostic imaging services, and rising awareness of early disease diagnosis continue to support regional market growth.
Brazil's market reached USD 0.12 billion in 2025. Growing investments in nuclear medicine, expanding diagnostic imaging centers, and increasing demand for advanced healthcare services continue to create growth opportunities across the country.
Middle East & Africa molybdenum-99 market accounted for 4.4% of the global market, totaling USD 0.18 billion in 2025, and is anticipated to grow at a CAGR of 6.88% during the forecast period. Rising healthcare investments, expanding diagnostic imaging capabilities, and increasing adoption of nuclear medicine technologies are supporting regional market growth.
The UAE market was valued at USD 0.06 billion in 2025. Government investments in advanced healthcare infrastructure, increasing availability of nuclear medicine services, and growing demand for early disease diagnosis continue to drive market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Practice Lead
Anantika Sharma is a research practice lead with 7+ years of experience in the food & beverage and consumer products sectors. She specializes in analyzing market trends, consumer behavior, and product innovation strategies. Anantika's leadership in research ensures actionable insights that enable brands to thrive in competitive markets. Her expertise bridges data analytics with strategic foresight, empowering stakeholders to make informed, growth-oriented decisions.
We are featured on:
sales@straitsresearch.com